PCSK9 inhibitors - clinical applications

Australian Prescriber

Volumn 39, Issue 5, 2016, Pages 168-170

  Schmidli, Robert ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Alirocumab; Bococizumab; Evolocumab; Ischaemic heart disease; LDL cholesterol; Proprotein convertase subtilisin kexin type 9

Indexed keywords

APOLIPOPROTEIN B100; CELL SURFACE RECEPTOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PCSK9 INHIBITOR; PROPROTEIN CONVERTASE 9; PROTEIN INHIBITOR; RNA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; DRUG MECHANISM; GENE; GENE EXPRESSION; GENE MUTATION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; LYSOSOME; NONHUMAN; PCSK9 GENE;

EID: 85017501819     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2016.061     Document Type: Article

References (15)

1. Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease - Australian facts: prevalence and incidence. Cardiovascular, diabetes and chronic kidney disease series no. 2. Cat. No. CDK 2. Canberra: AIHW; 2014. www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129549614. [cited 2016 Sep 1]
2. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14. http://dx.doi.org/10.1007/s10557-005-5686-z
3. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 2012;1:e001800. http://dx.doi.org/10.1161/JAHA.112.001800
4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. http://dx.doi.org/10.1056/NEJMoa1410489
5. Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, et al.; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8. http://dx.doi.org/10.2337/dc08-1543
6. Ferdinand KC, Nasser SA. PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a). Cardiovasc Drugs Ther 2015;29:295-308. http://dx.doi.org/10.1007/s10557-015-6588-3
7. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53. http://dx.doi.org/10.1016/j.jacc.2012.03.007
8. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17. http://dx.doi.org/10.1161/CIRCULATIONAHA.112.144055
9. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. http://dx.doi.org/10.1056/NEJMoa1500858
10. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al.; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99. http://dx.doi.org/10.1056/NEJMoa1501031
11. Praluent full prescribing information. Praluent (alirocumab) injection, for subcutaneous use. Initial US approval: 2015. http://www.regeneron.com/Praluent/Praluent-fpi.pdf [cited 2016 Sep 1]
12. Repatha full prescribing information. Repatha (evolocumab) injection, for subcutaneous use. Initial US approval: 2015. http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf [cited 2016 Sep 1]
13. Cicero AF, Colletti A, Borghi C. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther 2015;9:3073-82. http://dx.doi.org/10.2147/DDDT.S67498
14. Therapeutic Goods Administration. Prescription medicines: registration of new chemical entities in Australia, 2015. Canberra: Department of Health; 2016. www.tga.gov.au/prescription-medicines-registration-new-chemical-entitiesaustralia-2015. [cited 2016 Sep 1]
15. Evolocumab. Aust Prescr 2016;39:180-2. http://dx.doi.org/10.18773/austprescr.2016.078